High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer

M. L. Donato, D. Gershenson, C. Ippoliti, J. T. Wharton, R. C. Bast, A. Aleman, P. Anderlini, J. G. Gajewski, S. Giralt, J. Molldrem, N. Ueno, J. Lauppe, M. Korbling, J. Boyer, D. Bodurka-Bevers, M. Bevers, T. Burke, R. Freedman, C. Levenback, J. Wolf & 1 others R. E. Champlin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

High-dose chemotherapy combined with autologous peripheral blood stem cell transplantation has shown promise as treatment for recurrent or persistent epithelial ovarian cancer. We evaluated the stem cell mobilization regimen of high-dose ifosfamide plus etoposide in 32 patients with epithelial ovarian cancer, who had a positive second-look laparatomy or recurrent disease. Ifosfamide was given at 10 g/m2 by continuous i.v. from days 1 to 3. Etoposide was given at 150 mg/m2 every 12 h for six doses on days 1-3. Filgrastim was given at 10 μg/kg/d s.c. from day 5 until the completion of peripheral blood stem cell harvest. Fourteen of 32 patients had measurable or evaluable disease before mobilization therapy and were assessed for response. In nine (64%) of the 14 patients, treatment response was demonstrated, and these patients received a second cycle of mobilization therapy. The target CD34+ cell dose (> 8 x 106 cells/kg) was achieved with a median of one apheresis (range 1-5). A median of 25.1 (range 8.0-122.5) x 106 CD34+ cells/kg body weight was collected. Non-hematologic toxicity was limited to grade 2 renal dysfunction in one patient and grade 2 hepatic dysfunction in three patients. In this patient group, high-dose ifosfamide plus etoposide with filgrastim support was well tolerated, lead to successful stem cell harvest and had antitumor activity.

Original languageEnglish (US)
Pages (from-to)1137-1140
Number of pages4
JournalBone Marrow Transplantation
Volume25
Issue number11
StatePublished - 2000
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Mobilization
Ifosfamide
Etoposide
Ovarian Neoplasms
Peripheral Blood Stem Cell Transplantation
Blood Component Removal
Therapeutics
Filgrastim
Stem Cells
Body Weight
Kidney
Drug Therapy
Liver

Keywords

  • Etoposide
  • Ifosfamide
  • Ovarian cancer
  • Stem cell collection

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Donato, M. L., Gershenson, D., Ippoliti, C., Wharton, J. T., Bast, R. C., Aleman, A., ... Champlin, R. E. (2000). High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplantation, 25(11), 1137-1140.

High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. / Donato, M. L.; Gershenson, D.; Ippoliti, C.; Wharton, J. T.; Bast, R. C.; Aleman, A.; Anderlini, P.; Gajewski, J. G.; Giralt, S.; Molldrem, J.; Ueno, N.; Lauppe, J.; Korbling, M.; Boyer, J.; Bodurka-Bevers, D.; Bevers, M.; Burke, T.; Freedman, R.; Levenback, C.; Wolf, J.; Champlin, R. E.

In: Bone Marrow Transplantation, Vol. 25, No. 11, 2000, p. 1137-1140.

Research output: Contribution to journalArticle

Donato, ML, Gershenson, D, Ippoliti, C, Wharton, JT, Bast, RC, Aleman, A, Anderlini, P, Gajewski, JG, Giralt, S, Molldrem, J, Ueno, N, Lauppe, J, Korbling, M, Boyer, J, Bodurka-Bevers, D, Bevers, M, Burke, T, Freedman, R, Levenback, C, Wolf, J & Champlin, RE 2000, 'High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer', Bone Marrow Transplantation, vol. 25, no. 11, pp. 1137-1140.
Donato ML, Gershenson D, Ippoliti C, Wharton JT, Bast RC, Aleman A et al. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplantation. 2000;25(11):1137-1140.
Donato, M. L. ; Gershenson, D. ; Ippoliti, C. ; Wharton, J. T. ; Bast, R. C. ; Aleman, A. ; Anderlini, P. ; Gajewski, J. G. ; Giralt, S. ; Molldrem, J. ; Ueno, N. ; Lauppe, J. ; Korbling, M. ; Boyer, J. ; Bodurka-Bevers, D. ; Bevers, M. ; Burke, T. ; Freedman, R. ; Levenback, C. ; Wolf, J. ; Champlin, R. E. / High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. In: Bone Marrow Transplantation. 2000 ; Vol. 25, No. 11. pp. 1137-1140.
@article{a3f0a6e99ddc497b8e2953e9277e2735,
title = "High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer",
abstract = "High-dose chemotherapy combined with autologous peripheral blood stem cell transplantation has shown promise as treatment for recurrent or persistent epithelial ovarian cancer. We evaluated the stem cell mobilization regimen of high-dose ifosfamide plus etoposide in 32 patients with epithelial ovarian cancer, who had a positive second-look laparatomy or recurrent disease. Ifosfamide was given at 10 g/m2 by continuous i.v. from days 1 to 3. Etoposide was given at 150 mg/m2 every 12 h for six doses on days 1-3. Filgrastim was given at 10 μg/kg/d s.c. from day 5 until the completion of peripheral blood stem cell harvest. Fourteen of 32 patients had measurable or evaluable disease before mobilization therapy and were assessed for response. In nine (64{\%}) of the 14 patients, treatment response was demonstrated, and these patients received a second cycle of mobilization therapy. The target CD34+ cell dose (> 8 x 106 cells/kg) was achieved with a median of one apheresis (range 1-5). A median of 25.1 (range 8.0-122.5) x 106 CD34+ cells/kg body weight was collected. Non-hematologic toxicity was limited to grade 2 renal dysfunction in one patient and grade 2 hepatic dysfunction in three patients. In this patient group, high-dose ifosfamide plus etoposide with filgrastim support was well tolerated, lead to successful stem cell harvest and had antitumor activity.",
keywords = "Etoposide, Ifosfamide, Ovarian cancer, Stem cell collection",
author = "Donato, {M. L.} and D. Gershenson and C. Ippoliti and Wharton, {J. T.} and Bast, {R. C.} and A. Aleman and P. Anderlini and Gajewski, {J. G.} and S. Giralt and J. Molldrem and N. Ueno and J. Lauppe and M. Korbling and J. Boyer and D. Bodurka-Bevers and M. Bevers and T. Burke and R. Freedman and C. Levenback and J. Wolf and Champlin, {R. E.}",
year = "2000",
language = "English (US)",
volume = "25",
pages = "1137--1140",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer

AU - Donato, M. L.

AU - Gershenson, D.

AU - Ippoliti, C.

AU - Wharton, J. T.

AU - Bast, R. C.

AU - Aleman, A.

AU - Anderlini, P.

AU - Gajewski, J. G.

AU - Giralt, S.

AU - Molldrem, J.

AU - Ueno, N.

AU - Lauppe, J.

AU - Korbling, M.

AU - Boyer, J.

AU - Bodurka-Bevers, D.

AU - Bevers, M.

AU - Burke, T.

AU - Freedman, R.

AU - Levenback, C.

AU - Wolf, J.

AU - Champlin, R. E.

PY - 2000

Y1 - 2000

N2 - High-dose chemotherapy combined with autologous peripheral blood stem cell transplantation has shown promise as treatment for recurrent or persistent epithelial ovarian cancer. We evaluated the stem cell mobilization regimen of high-dose ifosfamide plus etoposide in 32 patients with epithelial ovarian cancer, who had a positive second-look laparatomy or recurrent disease. Ifosfamide was given at 10 g/m2 by continuous i.v. from days 1 to 3. Etoposide was given at 150 mg/m2 every 12 h for six doses on days 1-3. Filgrastim was given at 10 μg/kg/d s.c. from day 5 until the completion of peripheral blood stem cell harvest. Fourteen of 32 patients had measurable or evaluable disease before mobilization therapy and were assessed for response. In nine (64%) of the 14 patients, treatment response was demonstrated, and these patients received a second cycle of mobilization therapy. The target CD34+ cell dose (> 8 x 106 cells/kg) was achieved with a median of one apheresis (range 1-5). A median of 25.1 (range 8.0-122.5) x 106 CD34+ cells/kg body weight was collected. Non-hematologic toxicity was limited to grade 2 renal dysfunction in one patient and grade 2 hepatic dysfunction in three patients. In this patient group, high-dose ifosfamide plus etoposide with filgrastim support was well tolerated, lead to successful stem cell harvest and had antitumor activity.

AB - High-dose chemotherapy combined with autologous peripheral blood stem cell transplantation has shown promise as treatment for recurrent or persistent epithelial ovarian cancer. We evaluated the stem cell mobilization regimen of high-dose ifosfamide plus etoposide in 32 patients with epithelial ovarian cancer, who had a positive second-look laparatomy or recurrent disease. Ifosfamide was given at 10 g/m2 by continuous i.v. from days 1 to 3. Etoposide was given at 150 mg/m2 every 12 h for six doses on days 1-3. Filgrastim was given at 10 μg/kg/d s.c. from day 5 until the completion of peripheral blood stem cell harvest. Fourteen of 32 patients had measurable or evaluable disease before mobilization therapy and were assessed for response. In nine (64%) of the 14 patients, treatment response was demonstrated, and these patients received a second cycle of mobilization therapy. The target CD34+ cell dose (> 8 x 106 cells/kg) was achieved with a median of one apheresis (range 1-5). A median of 25.1 (range 8.0-122.5) x 106 CD34+ cells/kg body weight was collected. Non-hematologic toxicity was limited to grade 2 renal dysfunction in one patient and grade 2 hepatic dysfunction in three patients. In this patient group, high-dose ifosfamide plus etoposide with filgrastim support was well tolerated, lead to successful stem cell harvest and had antitumor activity.

KW - Etoposide

KW - Ifosfamide

KW - Ovarian cancer

KW - Stem cell collection

UR - http://www.scopus.com/inward/record.url?scp=0034118282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034118282&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 1137

EP - 1140

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 11

ER -